James Herriott Net Worth

The estimated Net Worth of James Herriott is at least $1.14 million dollars as of 30 April 2024. James Herriott owns over 30 units of Exact Sciences stock worth over $632,608 and over the last 2 years James sold EXAS stock worth over $504,462.

James Herriott EXAS stock SEC Form 4 insiders trading

James has made over 12 trades of the Exact Sciences stock since 2023, according to the Form 4 filled with the SEC. Most recently James sold 30 units of EXAS stock worth $1,805 on 30 April 2024.

The largest trade James's ever made was selling 2,225 units of Exact Sciences stock on 27 February 2023 worth over $134,457. On average, James trades about 1,037 units every 34 days since 2023. As of 30 April 2024 James still owns at least 9,866 units of Exact Sciences stock.

You can see the complete history of James Herriott stock trades at the bottom of the page.

What's James Herriott's mailing address?

James's mailing address filed with the SEC is C/O EXACT SCIENCES CORP., 5505 ENDEAVOR LANE, MADISON, WI, 53719.

Insiders trading at Exact Sciences

Over the last 21 years, insiders at Exact Sciences have traded over $118,141,352 worth of Exact Sciences stock and bought 191,930 units worth $1,451,887 . The most active insiders traders include Kevin T Conroy, Edwin M Jr Kania et Maneesh Arora. On average, Exact Sciences executives and independent directors trade stock every 12 days with the average trade being worth of $1,667,056. The most recent stock trade was executed by Brian Baranick on 5 August 2024, trading 2,712 units of EXAS stock currently worth $173,893.

What does Exact Sciences do?

exact sciences is a molecular diagnostics company focused on colorectal cancer. the company has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal cancer. stool-based dna (sdna) technology is included in the colorectal cancer screening guidelines of the american cancer society and the u.s. multi-society task force on colorectal cancer. for more information on exact sciences'​ noninvasive colon cancer screening test, visit cologuardtest.com

Complete history of James Herriott stock trades at Exact Sciences

Exact Sciences executives and stock owners

Exact Sciences executives and other stock owners filed with the SEC include:

• Kevin Conroy,
  Chairman of the Board, President, Chief Executive Officer
• Mark Stenhouse,
  General Manager - Screening
• Jeffrey Elliott,
  Chief Financial Officer
• D. Scott Coward,
  Senior Vice President, Chief Administrative Officer, General Counsel, Secretary
• Jake Orville,
  General Manager - Pipeline
• Ana Hooker,
  Senior Vice President, Operations
• Graham Lidgard,
  Senior Vice President, Chief Scientific Officer
• Kevin T. Conroy,
  Chairman, Pres & CEO
• G. Bradley Cole,
  Gen. Mang. of Precision Oncology
• Mark Stenhouse,
  Advisor
• Graham P. Lidgard,
  Emeritus Chief Science Officer
• Jeffrey T. Elliott CFA,
  Exec. VP, CFO & COO
• D. Scott Coward,
  Chief Admin. Officer, Exec. VP, Gen. Counsel & Sec.
• Kathleen Sebelius,
  Independent Director
• Andrew Slavitt,
  Director
• Pierre Jacquet,
  Independent Director
• Jake Orville,
  Gen. Mang. of Pipeline
• Ana Hooker,
  Sr. VP of Operations
• James Doyle,
  Independent Director
• Michael Wyzga,
  Independent Director
• Daniel Levangie,
  Independent Director
• Katherine Zanotti,
  Independent Director
• Thomas Carey,
  Independent Director
• Shacey Petrovic,
  Director
• Gisela Paulsen,
  General Manager - Precision Oncology
• Torsten Hoof,
  General Manager - International
• Freda Lewis-Hall,
  Independent Director
• Scott Johnson,
  Senior Vice President, Research and Development
• Vic Parker,
  Head of Sales
• Tim Caprez,
  Chief Compliance Counsel & VP
• Megan Jones,
  Associate Mang. of Investor Relations
• Dr. Scott C. Johnson Ph.D.,
  Chief Science Officer and Sr. VP of R&D
• Gary Frings,
  Chief Information Officer
• Lionel Sterling,
  Director
• John A. Fallon,
  Director
• David Thompson,
  Director
• G Bradley Cole,
  General Manager - Diagnostics
• Paul J Clancy,
  
• Michael J Barber,
  
• Eli Casdin,
  Director
• Anthony P Shuber,
  Executive Vice President
• John A Jr Mccarthy,
  Chief Financial Officer
• Don M Hardison,
  President, CEO and Director
• Barry M Berger,
  SVP, Chief Medical Officer
• William J. Megan,
  SVP, Finance & PFO
• John K Bakewell,
  Chief Financial Officer
• Jeffrey R Luber,
  General Counsel
• Edwin M Jr Kania,
  Director
• Charles R Jr Carelli,
  Prin. Acct. Off. & Corp. Ctlr.
• Patrick J Zenner,
  Director
• Stanley N Lapidus,
  Director
• John M Krayacich,
  SVP, Sales and Marketing
• Richard W Barker,
  Director
• Laura S Stoltenberg,
  Chief Commercial Officer
• Cornelius Iii Mcgillicudy,
  Director
• Harry W Wilcox,
  Senior Vice President and CFO
• Lance Willsey,
  Director
• Michael E Singer,
  Director
• Maneesh Arora,
  Vice President
• James P Connelly,
  Director
• Sally Crawford,
  Director
• Sarah Condella,
  EVP, Human Resources
• Timothy J Scannell,
  Director
• James Herriott,
  SVP, General Counsel & Sec
• Everett Cunningham,
  Chief Commercial Officer
• Jacob A Orville,
  EVP, GM, Screening
• Brian Baranick,
  EVP, GM, Precision Oncology